Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

Conditional survival (CS) is a clinically useful prediction measure which adjusts a patient's prognosis based on their duration of survival since initiation of therapy. CS has been described in numerous malignancies, and recently described in patients with metastatic renal cell carcinoma (mRCC)...

Full description

Saved in:
Bibliographic Details
Published in:Ecancermedicalscience 2016-09, Vol.10, p.676-676
Main Authors: Gill, David M, Stenehjem, David D, Parikh, Kinjal, Merriman, Joseph, Sendilnathan, Arun, Agarwal, Archana M, Hahn, Andrew W, Gupta, Sumati, Tantravahi, Srinivas Kiran, Samlowski, Wolfram E, Agarwal, Neeraj
Format: Article
Language:English
Subjects:
Cancer therapies
Clinical Study
Consortia
Counseling
Decision making
Immunotherapy
Kidney cancer
Laboratories
Medical prognosis
Metastasis
Oncology
Patients
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conditional survival (CS) is a clinically useful prediction measure which adjusts a patient's prognosis based on their duration of survival since initiation of therapy. CS has been described in numerous malignancies, and recently described in patients with metastatic renal cell carcinoma (mRCC) who received vascular endothelial growth factor tyrosine kinase inhibitor (VEGFTKI) therapy. However, CS has been not reported in the context of mRCC treated with high-dose interleukin-2 therapy (HDIL-2). A total of 176 patients with histologically confirmed metastatic clear cell RCC (mccRCC) treated with HDIL-2 at the University of Utah Huntsman Cancer Institute from 1988-2012 were evaluated. Using the Heng/IMDC model, they were stratified by performance status and prognostic risk groups. Two-year CS was defined as the probability of surviving an additional two years from initiation of HDIL-2 to 18 months after the start of HDIL-2 at three-month intervals. The median overall survival (OS) was 19.9 months. Stratifying patients into favourable (n = 35; 20%), intermediate (n = 110; 63%), and poor (n = 31; 18%) prognostic groups resulted in median OS of 47.5 (HR 0.57, 95% CI 0.35-0.88, p = 0.0106 versus intermediate), 19.6 (HR 0.33, 95% CI 0.10-0.33, p < 0.0001 versus poor), and 8.8 (HR 5.34, 95% CI 3.00-9.62, p < 0.0001 versus favourable) months respectively. Two-year overall CS increased from 43% at therapy initiation to 100% at 18 months. These results have significant ramifications in prognostication. Furthermore, it is important when counseling patients with mccRCC who have completed treatment with HDIL-2 and are in active follow-up.
ISSN:1754-6605
1754-6605
DOI:10.3332/ecancer.2016.676